House Expected To Eliminate Earmarks, give NCI $2 Billion For FY94, A $40 Million Increase
In Brief: Gene Therapy For ADA Deficiency Moves forward With Stem Cell Treatment In Caif. And At NIH
ACS Initiates Cage In Approach to Study Of alternative Methods
DT Board Oks RFAs In Surgery, HIV, Breast Cancer
Patient Costs In Trials Should Be Paid In Any Reform Plan, DCT Board Write To Shalala
FDA Simplifies Reporting Of Adverse Events
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Anthony Letai pledges to ensure stability for extramural and intramural cancer science









